Month: February 2021

Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds

Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western AustraliaStudy led by world leading burn...

Recce Pharmaceuticals Announces Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2

RECCE® 327 RT-PCR and Cell Viability Data RECCE® 327 RT-PCR and Cell Viability Data Highlights: RECCE® 327, a synthetic anti-infective...

PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections

Top-line Data Anticipated by Year End 2021 Enrollment Also Continues to Progress in Company’s Second Phase 3 Clinical Trial, SHIELD...

error: Content is protected !!